AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide
Authors: Huitema, ADR Mathot, RAA Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide, J PHARMA PH, 28(3), 2001, pp. 211-230
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma
Authors: Huitema, ADR Reinders, C Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma, J CHROMAT B, 757(2), 2001, pp. 349-357
Urinary excretion of thioTEPA and its metabolites in patients treated withhigh-dose cyclophosphamide, thioTEPA and carboplatin
Authors: van Maanen, MJ Huitema, ADR Rodenhuis, S Beijnen, JH
Citation: Mj. Van Maanen et al., Urinary excretion of thioTEPA and its metabolites in patients treated withhigh-dose cyclophosphamide, thioTEPA and carboplatin, ANTI-CANC D, 12(6), 2001, pp. 519-524
High-dose chemotherapy in breast cancer - interpretation of the randomizedtrials
Authors: Rodenhuis, S
Citation: S. Rodenhuis, High-dose chemotherapy in breast cancer - interpretation of the randomizedtrials, ANTI-CANC D, 12(2), 2001, pp. 85-88
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy
Authors: Huitema, ADR Mathot, RAA Tibben, MM Schellens, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy, BR J CL PH, 51(1), 2001, pp. 61-70
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer
Authors: Schrama, JG Baars, JW Holtkamp, MJ Schornagel, JH Beijnen, JH Rodenhuis, S
Citation: Jg. Schrama et al., Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer, BONE MAR TR, 28(2), 2001, pp. 173-180
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen
Authors: Huitema, ADR Mathot, RAA Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen, THER DRUG M, 23(6), 2001, pp. 650-657
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamideand metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma
Authors: Kerbusch, T Mathot, RAA Keizer, HJ Ouwerkerk, J Rodenhuis, S Schellens, JHM Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics and exploratory pharmacodynamics of ifosfamideand metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma, EUR J CL PH, 57(6-7), 2001, pp. 467-477
In vitro migratory capacity of CD34(+) cells is related to hematopoietic recovery after autologous stem cell transplantation
Authors: Voermans, C Kooi, MLK Rodenhuis, S van der Lelie, H van der Schoot, GE Gerritsen, WR
Citation: C. Voermans et al., In vitro migratory capacity of CD34(+) cells is related to hematopoietic recovery after autologous stem cell transplantation, BLOOD, 97(3), 2001, pp. 799-804
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer
Authors: Rodenhuis, S Huitema, ADR van Dam, FSAM de Vries, EGE Beijnen, JH
Citation: S. Rodenhuis et al., High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer, CANCER J, 6, 2000, pp. S125-S130
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
Authors: Huitema, ADR Tibben, MM Kerbusch, T Kettenes-van den Bosch, JJ Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography, J CHROMAT B, 745(2), 2000, pp. 345-355
High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red bloodcells
Authors: Huitema, ADR Tibben, MM Kerbusch, T Kettenes-van den Bosch, JJ Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red bloodcells, J LIQ CHR R, 23(11), 2000, pp. 1725-1744
The clinical pharmacology of alkylating agents in high-dose chemotherapy
Authors: Huitema, ADR Smits, KD Mathot, RAA Schellans, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., The clinical pharmacology of alkylating agents in high-dose chemotherapy, ANTI-CANC D, 11(7), 2000, pp. 515-533
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
Authors: Le Cesne, A Judson, I Crowther, D Rodenhuis, S Keizer, HJ Van Hoesel, Q Blay, JY Frisch, J Van Glabbeke, M Hermans, C Van Oosterom, A Tursz, T Verweij, J
Citation: A. Le Cesne et al., Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, J CL ONCOL, 18(14), 2000, pp. 2676-2684
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens
Authors: Huitema, ADR Kerbusch, T Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens, CANC CHEMOT, 46(2), 2000, pp. 119-127
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy
Authors: Westermann, AR Dubbelman, R Baars, JP Moolenaar, WH Beijnen, JH Rodenhuis, S
Citation: Ar. Westermann et al., Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy, CANC CHEMOT, 46(1), 2000, pp. 57-62
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion
Authors: Rosing, H Lustig, V van Warmerdam, LJC Huizing, MT Huinink, WWT Schellens, JHM Rodenhuis, S Bult, A Beijnen, JH
Citation: H. Rosing et al., Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion, CANC CHEMOT, 45(3), 2000, pp. 213-218
Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
Authors: Huitema, ADR Mathot, RAA Tibben, MM Schellens, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods, CLIN PHARM, 67(6), 2000, pp. 621-630
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group
Authors: Woll, PJ Judson, I Lee, SM Rodenhuis, S Nielsen, OS Buesa, JM Lorigan, PC Leyvraz, S Hermans, C van Glabbeke, M Verweij, J
Citation: Pj. Woll et al., Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group, EUR J CANC, 35(3), 1999, pp. 410-412
Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens
Authors: Blay, JY Judson, I Rodenhuis, S Hermans, C Smith, M van Glabbeke, M Verweij, J
Citation: Jy. Blay et al., Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens, ANTI-CANC D, 10(10), 1999, pp. 873-877
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study
Authors: van Gijn, R Huinink, WWT Rodenhuis, S Vermorken, JB van Tellingen, O Rosing, H van Warmerdam, LJC Beijnen, JH
Citation: R. Van Gijn et al., Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study, ANTI-CANC D, 10(1), 1999, pp. 17-23
At home management of aplastic phase following high-dose chemotherapy withstem-cell rescue for hematological and non-hematological malignancies
Authors: Westermann, AM Holtkamp, MMJ Linthorst, GAM van Leeuwen, L Willemse, EJM van Dijk, WC Nooijen, WJ Baars, JW Schornagel, JH Rodenhuis, S
Citation: Am. Westermann et al., At home management of aplastic phase following high-dose chemotherapy withstem-cell rescue for hematological and non-hematological malignancies, ANN ONCOL, 10(5), 1999, pp. 511-517
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
Authors: Rodenhuis, S de Wit, R de Mulder, PHM Keizer, HJ Sleijfer, DT Lalisang, RI Bakker, PJM Mandjes, I Kooi, M de Vries, EGE
Citation: S. Rodenhuis et al., A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission, ANN ONCOL, 10(12), 1999, pp. 1467-1473
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen
Authors: Panday, VRN van Warmerdam, LJC Huizing, MT Rodenhuis, S Schellens, JHM Beijnen, JH
Citation: Vrn. Panday et al., A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen, CANC CHEMOT, 43(5), 1999, pp. 435-438
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells
Authors: Lambrechts, AC Bosma, AJ Klaver, SG Top, B Perebolte, L van't Veer, LJ Rodenhuis, S
Citation: Ac. Lambrechts et al., Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells, BREAST CANC, 56(3), 1999, pp. 219-231
Risultati: 1-25 | 26-30